Elena Anghileri

Medicine & Life Sciences

1. Glioblastoma 100%
2. Glioma 58%
3. Temozolomide 56%
4. alpha-hydroxyglutarate 42%
5. Fluorescein 37%
6. Central Nervous System 36%
7. Medulloblastoma 32%
8. Multicenter Studies 30%
9. osimertinib 27%
10. Survival 27%
11. Dendritic Cells 25%
12. Prospective Studies 24%
13. Mesenchymal Stem Cells 23%
14. Cerebrospinal Fluid 22%
15. Drug Therapy 22%
16. Neoplasms 22%
17. Lymphoma 21%
18. Mutation 21%
19. Brain 21%
20. Irinotecan 20%
21. Bevacizumab 20%
22. depatuxizumab mafodotin 20%
23. Neoplasm Metastasis 19%
24. Adenocarcinoma of Lung 18%
25. Neurology 18%
26. Retrospective Studies 17%
27. Natural Killer Cells 17%
28. Immunotherapy 17%
29. Autoantigens 17%
30. Radiotherapy 17%
31. Autoimmune Experimental Encephalomyelitis 17%
32. Multiple Sclerosis 17%
33. ErbB Receptors 16%
34. Acute Hemorrhagic Leukoencephalitis 15%
35. 2-Hydroxyglutaricaciduria 15%
36. Interleukin-10 15%
37. Tumor Burden 14%
38. Observational Studies 14%
39. Magnetic Resonance Spectroscopy 13%
40. Catheters 13%
41. T-Lymphocytes 13%
42. Therapeutics 13%
43. Immunoglobulin G 13%
44. Brain Neoplasms 12%
45. Hashimoto's encephalitis 12%
46. Neuroepithelial Neoplasms 12%
47. Progression-Free Survival 12%
48. Sumatriptan 12%
49. Cluster Headache 12%
50. Carcinoma 11%